The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias
Parkinson's disease (PD) is a neurodegenerative movement disorder that is routinely treated with levodopa. Unfortunately, long-term dopamine replacement therapy using levodopa leads to levodopa-induced dyskinesias (LID), a significant and disabling side-effect. Clinical findings indicate that L...
Main Authors: | Vishakh Iyer, Kala Venkiteswaran, Sandip Savaliya, Christopher A. Lieu, Erin Handly, Timothy P. Gilmour, Allen R. Kunselman, Thyagarajan Subramanian |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-11-01
|
Series: | Neurobiology of Disease |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996121002400 |
Similar Items
-
Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?
by: Paolo Calabresi, et al.
Published: (2019-12-01) -
Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
by: Destany K. Kwon, et al.
Published: (2022-11-01) -
Continuous long-range measurement of tonic dopamine with advanced FSCV for pharmacodynamic analysis of levodopa-induced dyskinesia in Parkinson’s disease
by: Jeongrak Park, et al.
Published: (2024-01-01) -
Discinesias induzidas por levodopa em 176 pacientes com doença de Parkinson Levodopa-induced dyskinesias in 176 parkisonian patients
by: Maria Sheila G. Rocha, et al.
Published: (1995-12-01) -
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
by: Nayron Medeiros Soares, et al.
Published: (2023-01-01)